Tianjin Zhongxin Pharmaceutical Group Corp Ltd (600329) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Tianjin Zhongxin Pharmaceutical Group Corp Ltd (600329) has a cash flow conversion efficiency ratio of 0.012x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥110.78 Million ≈ $16.21 Million USD) by net assets (CN¥9.02 Billion ≈ $1.32 Billion USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Tianjin Zhongxin Pharmaceutical Group Co (600329) market capitalisation for the company's overall valuation and market capitalisation.
Tianjin Zhongxin Pharmaceutical Group Corp Ltd - Cash Flow Conversion Efficiency Trend (2001–2024)
This chart illustrates how Tianjin Zhongxin Pharmaceutical Group Corp Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Tianjin Zhongxin Pharmaceutical Group Corp Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Tianjin Zhongxin Pharmaceutical Group Corp Ltd ranked by their cash flow conversion efficiency. Explore Tianjin Zhongxin Pharmaceutical Group Co earnings quality ratio to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Fujian Newland Computer Co Ltd
SHE:000997
|
-0.027x |
|
Fujian Sunner Development Co Ltd
SHE:002299
|
0.143x |
|
SPS Commerce Inc
NASDAQ:SPSC
|
0.070x |
|
Plug Power Inc
NASDAQ:PLUG
|
-0.160x |
|
SpareBank 1 Østlandet
OL:SPOL
|
-0.018x |
|
ABM Industries Incorporated
NYSE:ABM
|
0.082x |
|
Himadri Speciality Chemical Limited
NSE:HSCL
|
-0.020x |
|
Immunome Inc
NASDAQ:IMNM
|
-0.117x |
Annual Cash Flow Conversion Efficiency for Tianjin Zhongxin Pharmaceutical Group Corp Ltd (2001–2024)
The table below shows the annual cash flow conversion efficiency of Tianjin Zhongxin Pharmaceutical Group Corp Ltd from 2001 to 2024. View 600329 share price today for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | CN¥7.85 Billion ≈ $1.15 Billion |
CN¥924.67 Million ≈ $135.31 Million |
0.118x | +13.69% |
| 2023-12-31 | CN¥6.65 Billion ≈ $972.41 Million |
CN¥688.49 Million ≈ $100.75 Million |
0.104x | +0.23% |
| 2022-12-31 | CN¥6.55 Billion ≈ $958.76 Million |
CN¥677.25 Million ≈ $99.10 Million |
0.103x | -21.01% |
| 2021-12-31 | CN¥6.51 Billion ≈ $953.18 Million |
CN¥852.40 Million ≈ $124.73 Million |
0.131x | +15.96% |
| 2020-12-31 | CN¥5.95 Billion ≈ $870.66 Million |
CN¥671.42 Million ≈ $98.25 Million |
0.113x | +25.79% |
| 2019-12-31 | CN¥5.52 Billion ≈ $808.22 Million |
CN¥495.49 Million ≈ $72.51 Million |
0.090x | +29.50% |
| 2018-12-31 | CN¥5.05 Billion ≈ $739.62 Million |
CN¥350.14 Million ≈ $51.24 Million |
0.069x | +8165.98% |
| 2017-12-31 | CN¥4.63 Billion ≈ $676.85 Million |
CN¥-3.97 Million ≈ $-581.32K |
-0.001x | -100.88% |
| 2016-12-31 | CN¥4.30 Billion ≈ $629.56 Million |
CN¥419.90 Million ≈ $61.44 Million |
0.098x | +11.12% |
| 2015-12-31 | CN¥4.11 Billion ≈ $600.72 Million |
CN¥360.58 Million ≈ $52.76 Million |
0.088x | -9.77% |
| 2014-12-31 | CN¥2.95 Billion ≈ $431.19 Million |
CN¥286.85 Million ≈ $41.98 Million |
0.097x | +17.45% |
| 2013-12-31 | CN¥2.57 Billion ≈ $376.80 Million |
CN¥213.44 Million ≈ $31.23 Million |
0.083x | +807.71% |
| 2012-12-31 | CN¥2.28 Billion ≈ $333.46 Million |
CN¥20.81 Million ≈ $3.04 Million |
0.009x | -88.42% |
| 2011-12-31 | CN¥2.21 Billion ≈ $322.67 Million |
CN¥173.88 Million ≈ $25.44 Million |
0.079x | +18.36% |
| 2010-12-31 | CN¥2.09 Billion ≈ $305.38 Million |
CN¥139.04 Million ≈ $20.35 Million |
0.067x | +42.83% |
| 2009-12-31 | CN¥1.79 Billion ≈ $261.66 Million |
CN¥83.41 Million ≈ $12.21 Million |
0.047x | -55.90% |
| 2008-12-31 | CN¥1.47 Billion ≈ $215.50 Million |
CN¥155.77 Million ≈ $22.79 Million |
0.106x | +606.94% |
| 2007-12-31 | CN¥1.35 Billion ≈ $196.89 Million |
CN¥20.13 Million ≈ $2.95 Million |
0.015x | +175.03% |
| 2006-12-31 | CN¥1.41 Billion ≈ $206.07 Million |
CN¥-28.08 Million ≈ $-4.11 Million |
-0.020x | -114.84% |
| 2005-12-31 | CN¥1.95 Billion ≈ $285.17 Million |
CN¥261.91 Million ≈ $38.33 Million |
0.134x | +2304.03% |
| 2004-12-31 | CN¥1.88 Billion ≈ $274.74 Million |
CN¥10.50 Million ≈ $1.54 Million |
0.006x | -86.57% |
| 2003-12-31 | CN¥1.84 Billion ≈ $269.08 Million |
CN¥76.57 Million ≈ $11.20 Million |
0.042x | -62.51% |
| 2002-12-31 | CN¥1.69 Billion ≈ $247.19 Million |
CN¥187.60 Million ≈ $27.45 Million |
0.111x | +8.52% |
| 2001-12-31 | CN¥1.54 Billion ≈ $225.52 Million |
CN¥157.73 Million ≈ $23.08 Million |
0.102x | -- |
About Tianjin Zhongxin Pharmaceutical Group Corp Ltd
Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited engages in the research, development, processing, manufacturing, and sale of traditional Chinese medicine in China. It provides pharmaceutical products for cardiovascular and cerebrovascular, skin wound repair, health preservation, respiratory, digestion, rheumatism and osteodynia, urological, gynecological and pediatric, ophthalmologic… Read more